Federal Circuit Upholds USPTO Discretion in Fintiv Denials

Patent lawyers love certainty the way toddlers love snack time: loudly, enthusiastically, and with dramatic consequences when it disappears. So when the Federal Circuit weighed in on the USPTO’s authority over Fintiv-based discretionary denials, the patent bar paid attention. The court’s recent ruling confirmed something many PTAB watchers already suspected: the agency still has a very long leash when deciding whether to institute inter partes review, especially when parallel district court litigation is already barreling ahead.

That matters because Fintiv denials sit right at the intersection of two worlds that already have enough tension to power a small city: district court patent litigation and PTAB review. Petitioners want a fast, expert venue to challenge patent claims. Patent owners want to avoid fighting the same war twice. And the USPTO? It wants to conserve resources, avoid conflicting outcomes, and keep the whole system from turning into a procedural food fight.

The Federal Circuit’s decision did not say every future Fintiv denial is automatically correct. But it did make clear that the USPTO Director has broad room to shape institution policy and that the NHK-Fintiv framework can survive an Administrative Procedure Act challenge without formal notice-and-comment rulemaking. In plain English: the attack on the rulemaking process fizzled, and agency discretion remains very much alive.

What the Federal Circuit Actually Held

The headline case is Apple v. Squires, the follow-on to the earlier Apple v. Vidal litigation. A group of major companies, led by Apple, challenged the Director’s instructions to the Patent Trial and Appeal Board on how to handle discretionary denial when parallel district court litigation overlaps with a requested IPR. Their argument was not subtle: these instructions were important enough, binding enough, and consequential enough that they should have gone through notice-and-comment rulemaking under the APA.

The Federal Circuit disagreed. It held that the challenged instructions were general statements of policy, not substantive legislative rules. That distinction is legal catnip in administrative law, because policy statements generally do not require notice-and-comment procedures. The court emphasized that Congress gave the Director broad discretion over whether to institute IPR in the first place. If institution is discretionary and the Director remains free to make the final call, guidance about how that discretion will usually be exercised does not necessarily become a legislative rule with the force of law.

That point did the heavy lifting. The court reasoned that the NHK-Fintiv instructions bind the Board as the Director’s delegatee, but they do not bind the Director herself. And because the Director retains the ultimate authority to institute or deny review, the framework remains a policy tool rather than a statute-sized commandment dropped from the mountaintop.

Just as important, the court stressed that a denial of institution does not alter the underlying patent rights themselves. The patent still lives or dies in district court, and the accused infringer can still raise invalidity defenses there. In other words, the non-institution decision may be painful, expensive, and strategically annoying, but it does not itself change the legal status of the patent in the way a legislative rule normally would.

A Quick Refresher: What Is a Fintiv Denial?

To understand why this case matters, it helps to revisit the creature at the center of the drama. Apple v. Fintiv, layered on top of the earlier NHK Spring decision, created a multi-factor framework the PTAB uses to decide whether to deny institution when there is parallel litigation involving the same patent. The idea is simple enough: if the district court case is already far along and likely to resolve overlapping issues before the PTAB can issue a final written decision, then maybe the Board should not jump into the pool wearing a full suit of procedural armor.

The traditional Fintiv factors include:

1. whether the district court has granted, or is likely to grant, a stay if IPR is instituted;
2. how close the court’s trial date is to the PTAB’s projected final written decision deadline;
3. how much investment the court and the parties have already made in the parallel case;
4. how much overlap exists between issues raised in the petition and issues already in litigation;
5. whether the petitioner and district court defendant are the same party; and
6. other circumstances, including the merits.

For years, these factors were both famous and infamous. Supporters said they prevented duplicative proceedings and gamesmanship. Critics said they let weak patents dodge PTAB scrutiny simply because a fast-moving court schedule made the Board nervous. And because some popular patent venues move quickly, especially in plaintiff-friendly districts, the time-to-trial factor often got star billing.

Why the Decision Is a Big Deal for PTAB Practice

The Federal Circuit’s ruling matters because it takes one of the strongest procedural attacks on the NHK-Fintiv framework and puts it in a neat little appellate box labeled not enough. The message is not that the USPTO can do literally anything. The message is that when Congress gives the Director broad institution discretion and shields much of that discretion from judicial review, the courts are not eager to turn PTAB institution guidance into an APA minefield.

That creates a more stable foundation for discretionary denial policy. If the agency wants to issue institution guidance, revise how discretionary considerations are handled, or centralize decision-making, challengers now face a steeper climb in arguing that the framework collapses simply because it did not pass through formal rulemaking.

For petitioners, that means the old hope of knocking out Fintiv as procedurally defective has faded. For patent owners, it means discretionary denial remains a serious tool, especially in cases where district court litigation is already sprinting while the PTAB is still tying its shoelaces.

The Post-Vidal, Post-Squires Landscape

Now for the plot twist. The law did not stand still while Apple’s APA challenge was working its way through the courts. In 2022, then-Director Kathi Vidal issued a memorandum that softened the practical force of Fintiv in several important ways. Under that memo, the PTAB would not deny institution based on parallel district court litigation when a petition presented compelling evidence of unpatentability, and a broad Sotera stipulation could effectively neutralize a Fintiv denial in many cases.

Then came February 2025. The USPTO rescinded that 2022 Vidal memo and told parties to look again to PTAB precedent, including Fintiv and Sotera. A month later, the Office rolled out an interim process for PTAB workload management that separated discretionary denial issues from merits issues and formalized additional briefing on discretionary considerations. Later in 2025, the agency further centralized institution authority in the Director.

That sequence matters because it shows the practical significance of Apple v. Squires. The Federal Circuit was not writing in a vacuum. It was affirming the agency’s freedom to use policy guidance in an area where the agency was already actively redesigning the institution process. So while the case is technically about APA procedure, its real-world effect is broader: it confirms that the USPTO can keep steering PTAB institution practice through policy-based mechanisms without immediately getting dragged into rulemaking quicksand.

What This Means for Petitioners

If you represent a petitioner, the lesson is straightforward: do not treat IPR institution as a box-checking exercise. Passing the merits threshold is necessary, but it is not enough. Timing, overlap, forum, and strategic positioning matter more than ever. A petitioner that files late, mirrors its district court invalidity positions too closely, and lands in a court with an aggressive schedule is basically handing the patent owner a pre-wrapped discretionary denial argument with a bow on top.

That also means Sotera stipulations still matter, but they are no longer magic. They remain useful for reducing overlap and showing efficiency, yet they do not guarantee institution the way petitioners once hoped. The broader theme is that discretionary factors have returned to being exactly what the label suggests: discretionary.

Smart petitioners should now think like litigators and traffic engineers at the same time. File early. Coordinate arguments across forums. Build a record that shows institution would streamline, not duplicate, the dispute. And do not assume a clever APA theory will save a weak filing strategy after the fact.

What This Means for Patent Owners

For patent owners, this decision is a very nice addition to the toolbox. It does not guarantee a discretionary denial, but it reinforces the legitimacy of arguing that parallel litigation should proceed without a duplicate PTAB proceeding chewing through time and resources. Patent owners with advanced district court cases, meaningful investment on the merits, and strong overlap arguments now have more than a vibe and a dream. They have a durable legal framework that the Federal Circuit has refused to uproot on procedural grounds.

That said, patent owners should not get too comfortable. The PTAB still considers the merits, and a compelling unpatentability case can make even a good discretionary-denial pitch wobble a bit. Patent owners still need a disciplined narrative: the case is moving, the court has invested heavily, the issues overlap substantially, and institution would not promote efficiency or integrity. In other words, the brief needs more than “please make this go away.” It needs receipts.

Specific Examples Showing the Trend

The trend line after Apple v. Squires is not subtle. The Federal Circuit has continued to reject attempts to use mandamus as a workaround for the general nonreviewability of institution decisions. Cases involving Motorola, Intel, Kahoot!, and Tesla all show the same basic theme: absent a genuinely colorable constitutional claim, the court is not excited about becoming the PTAB’s backseat driver.

That does not mean mandamus is dead in every conceivable scenario. But it does mean the “extraordinary remedy” label is doing real work. Petitioners arguing that the Director weighed the wrong factor, gave too much importance to parallel proceedings, or failed to follow preferred guidance have generally found the courthouse door only slightly more open than a brick wall.

So the practical lesson is becoming impossible to ignore: the fight over discretionary denial is increasingly won or lost inside the agency process, not on appellate cleanup duty after the denial arrives.

Why This Decision Matters Beyond Patent Procedure

There is also a bigger administrative-law point here. Apple v. Squires illustrates how much turns on whether agency guidance is treated as a binding rule or a policy statement. In areas where Congress grants broad discretion and limits judicial review, agencies have room to shape outcomes through policy guidance that is highly influential without necessarily triggering notice-and-comment obligations.

That does not mean agencies get a free pass forever. If the USPTO were to adopt a truly binding institution regime that effectively removed discretion or altered legal rights with the force of law, the analysis could look different. But the Federal Circuit saw the NHK-Fintiv framework as something more flexible, more advisory in form, and more closely tied to a discretionary decision Congress deliberately insulated.

That is why the case will likely be cited far beyond the immediate world of PTAB discretionary denials. It is a reminder that policy statements can still shape high-stakes outcomes, especially when the official decisionmaker retains ultimate authority and the underlying determination is not something Congress wanted courts reviewing every five minutes.

Practical Experience: What Fintiv Denials Feel Like in the Real World

Talk to lawyers and in-house teams who deal with repeat patent litigation, and you will hear a familiar story. The complaint lands. The district court case starts moving faster than anyone would prefer. Outside counsel begins mapping invalidity positions, prior art, and forum strategy. Someone says, “Let’s file an IPR.” Someone else says, “Great idea, but what’s the trial schedule?” And that is usually the moment the room gets just a little quieter.

The lived experience of Fintiv is not really about one doctrine in one opinion. It is about compression. Petitioners feel compressed by filing deadlines, district court schedules, and the fear that waiting to refine the prior art record will make the PTAB think the train has already left the station. Patent owners feel compressed by the possibility of fighting the same validity battle in two places at once, with two sets of experts, two procedural calendars, and two opportunities for things to go sideways before lunch.

For accused infringers, a discretionary denial often feels like being told, “Yes, you may challenge this patent, just not in the forum you were hoping for.” That can be frustrating because the PTAB is often seen as a technically sophisticated venue with judges who spend their days knee-deep in patent claims instead of juggling patent issues with an overflowing district court docket. When institution is denied under Fintiv, the petitioner still has its district court defenses, of course, but the strategy shifts from a potentially streamlined administrative challenge to full-blown litigation trench warfare.

For patent owners, the experience is almost the mirror image. A well-timed discretionary denial can feel like a pressure valve finally releasing. Instead of defending the same patent in two arenas, the owner can focus resources on the court case already underway. That does not make the litigation cheap or easy, but it can make it more coherent. And coherence, in patent disputes, is practically a luxury product.

There is also a behavioral effect. Since Fintiv became a major part of the institution calculus, parties have become more deliberate about forum timing, stipulations, and case-management strategy. Petitioners think harder about filing earlier and narrowing overlap. Patent owners think harder about emphasizing court investment, resisting stays, and building a record that district court proceedings are not hypothetical future events but real, resource-consuming present facts. In that sense, Fintiv has changed not only PTAB outcomes but also the way parties litigate before they even get to the Board.

And that may be the most important practical takeaway of all. Federal Circuit review has now reinforced that this discretionary world is not going away just because industry defendants dislike it. So the best responses are operational, not nostalgic. Petitioners need cleaner, earlier, better-coordinated IPR strategies. Patent owners need sharper efficiency arguments and stronger records. Everyone needs to stop pretending this is still a purely merits-driven institution system. It is a mixed system now: law, timing, overlap, discretion, and a little procedural weather forecasting thrown in for good measure.

Conclusion

The Federal Circuit’s endorsement of the USPTO’s room to manage Fintiv denials is a major development for PTAB practice. The court did not hold that every discretionary denial is right, wise, or immune from all future challenge. But it did hold that the NHK-Fintiv framework could stand without formal APA notice-and-comment rulemaking because it operates as a policy statement guiding a discretionary institution decision. That is a big win for agency flexibility and a big warning to petitioners hoping to dismantle the framework through procedural attacks.

In practical terms, the decision means USPTO discretion remains central to IPR institution. The 2025 rescission of the Vidal memo, the revised interim processes, and the later centralization of institution authority only amplify that reality. For patent owners, the ruling preserves a meaningful shield against duplicative PTAB proceedings. For petitioners, it raises the premium on timing, strategy, and record-building. And for the rest of the patent world, it confirms that the Fintiv debate has entered a new phase: less about whether the framework exists, and more about how aggressively the agency chooses to use it.